What it is
Eloralintide is a peptide made of 37 amino acids. It is made in a lab by Eli Lilly. It copies amylin, a hormone the pancreas releases with insulin after meals. Amylin slows how fast the stomach empties and signals the brain that you are full. Eloralintide has a fatty acid chain that sticks to albumin in the blood. This keeps it in the body for about 13 to 15 days. It was built to act mostly on one amylin receptor, called AMY1R. Cagrilintide acts on several amylin receptors at once. See the Cagrilintide entry for that compound. Other names: LY3841136.
What researchers study it for
- Body weight in adults with obesity
- Stomach side effects compared to other amylin drugs
- Fat loss compared to muscle loss in animals
- Pairing with tirzepatide
What the studies found
1. Weight dropped up to 20 percent in 48 weeks.
A 2025 phase 2 trial gave 263 adults with obesity or overweight a weekly shot of eloralintide at one of several doses, or placebo. None had type 2 diabetes. Weight dropped 9 percent at the lowest dose and 20 percent at the highest doses. The placebo group lost 0.4 percent. Weight was still dropping at week 48. Nausea and tiredness were the most common side effects, and both were lower when the dose was raised more slowly. Human data.
2. The first human study showed a long time in the blood.
This 2025 paper covered lab, rat, and first human tests. In lab cells, eloralintide acted on AMY1R about 12 times more strongly than on the calcitonin receptor. In 48 healthy adults, it stayed in the blood about 13 to 15 days after one shot. Rats given eloralintide lost less muscle than rats given cagrilintide. Most human side effects were mild. Lab, animal, and human data.
3. Twelve weeks of weekly shots cut weight up to 11.3 percent.
A 2026 phase 1 study gave 100 adults with obesity or overweight weekly shots or placebo for 12 weeks. Weight dropped 2.6 to 11.3 percent, depending on the dose. Nausea happened in 8 percent and vomiting in 4 percent. Lower appetite, headache, and tiredness were the most common side effects. Human data.
How much research exists
Two phase 1 studies and one phase 2 trial, all run by Eli Lilly. Phase 3 trials are recruiting. No data past 48 weeks. No head-to-head human trial against cagrilintide.
Facts
- Formula: C201H319N49O65S2
- Weight: about 4526 g/mol
- CAS number: 2883634-40-8 (could not confirm)
- Sequence: amylin-based peptide chain with a fatty acid chain attached. Full sequence not listed here.
- Time in the blood: about 13 to 15 days
- Storage: keep in the fridge. Do not freeze. Keep away from light.
Legal status
Not approved by the FDA or any other agency. It is an investigational drug. It is only available inside Eli Lilly trials.
For research use only. Not for human use. Nothing here is medical advice.